Michael W. Kalb serves as the Executive Vice President and Chief Financial Officer at Catalyst Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and epileptic diseases. In his role, Kalb is responsible for overseeing the financial strategy and operations of the company, ensuring its fiscal health and supporting its growth initiatives. His expertise in financial management and strategic planning has been instrumental in guiding Catalyst Pharmaceuticals through various stages of its development, from early-stage research to the successful commercialization of its products. Prior to joining Catalyst Pharmaceuticals, Michael W. Kalb held several high-profile positions in the finance and healthcare sectors. He has a robust background in corporate finance, having worked with both emerging biotech firms and established pharmaceutical companies. Kalb's career highlights include leading successful financings and mergers and acquisitions that have significantly contributed to the growth and stability of the organizations he has served. His strategic vision and leadership skills have earned him a reputation as a respected figure in the industry, capable of navigating complex financial landscapes and driving sustainable growth. Kalb's achievements at Catalyst Pharmaceuticals include playing a pivotal role in securing funding for critical research and development projects, as well as optimizing the company's financial structure to support its long-term objectives. Under his leadership, the company has achieved significant milestones, such as the successful launch of its flagship product, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). His contributions have not only bolstered the company's financial performance but also enhanced its reputation as a leader in the rare disease space. Michael W. Kalb's dedication to advancing healthcare solutions through sound financial management continues to be a driving force behind Catalyst Pharmaceuticals' success.